The intended extension of PARP inhibitors in cancer therapy aims at the non-homologous recombination DNA repair systems, signalling pathways, angiogenesis, or immune checkpoint mechanisms, all utilising the function of PARP in DNA repair. The gene discussed is PARP1; the disease is cancer.